News articles about Adverum Biotechnologies (NASDAQ:ADVM) have trended positive recently, Accern Sentiment reports. The research firm ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Adverum Biotechnologies earned a media sentiment score of 0.29 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 46.6421836146314 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Adverum Biotechnologies (NASDAQ ADVM) traded down 3.70% on Friday, hitting $2.60. 403,218 shares of the stock were exchanged. The stock’s 50 day moving average price is $2.56 and its 200 day moving average price is $2.69. Adverum Biotechnologies has a 52-week low of $2.40 and a 52-week high of $4.55. The firm’s market cap is $112.54 million.

A number of research firms have recently commented on ADVM. Zacks Investment Research upgraded shares of Adverum Biotechnologies from a “hold” rating to a “buy” rating and set a $2.75 price target on the stock in a report on Wednesday, August 16th. ValuEngine cut shares of Adverum Biotechnologies from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd.

TRADEMARK VIOLATION NOTICE: This news story was originally posted by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this news story can be accessed at

About Adverum Biotechnologies

Adverum Biotechnologies, Inc, formerly Avalanche Biotechnologies, Inc, is a gene therapy company. The Company is engaged in discovering and developing medicines to patients suffering from chronic or debilitating disease. The Company operates and manages its business in the segment of developing and commercializing gene therapeutics.

Receive News & Ratings for Adverum Biotechnologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adverum Biotechnologies Inc. and related companies with's FREE daily email newsletter.